The first recombinant protein new crown vaccine produced by insect cells in China was approved by national clinical trial

, ,

,

Chengdu full search news network, August 22 – on August 21, the recombinant protein new crown vaccine developed by the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, was approved by the State Drug Administration for clinical trials. It is reported that the research and development process of the vaccine has been strongly supported by the Ministry of science and technology, the National Health Commission, the State Food and drug administration, the Ministry of education, Sichuan Province, Chengdu City and other departments, as well as the strong support and cooperation of many domestic scientific research institutions.

the vaccine targets the spike protein receptor binding domain (s-rbd) of sars-cov-2 and produces neutralizing antibodies to block the virus from infecting human cells. As early as July 29, researchers from the laboratory published relevant research papers in the world famous journal Nature, which is also the first new crown vaccine published in Nature magazine since the new crown epidemic this year. The cov-2 vaccine was found to have no obvious side effects in animals infected with SARS.

and

recombinant protein new crown vaccine of West China Biological Laboratory of Sichuan University propagates in large quantities in the culture medium, and the gene of new coronavirus is introduced into insect cells. The cell is used as a factory to produce high-quality recombinant vaccine protein, which is purified and refined. This technology is easy to be put into the market quickly and on a large scale. It is reported that the use of insects to produce recombinant protein vaccine, in Europe and the United States and other countries have cervical cancer vaccine and influenza vaccine and other products on the market, its application safety in human body has been verified.

,

, ,

,

in order to promote the clinical trial and marketing of vaccines as soon as possible, Chengdu Tianfu international biological city has given full play to the advantages of “pilot and demonstration base for the transfer and transformation of major national scientific and technological achievements of major new drug creation”. At the beginning of the project research, Chengdu Tianfu international biological city kept close contact with each other, and intervened early to design the transformation path.

and

in April this year, West China Hospital of Sichuan University, vaccine research team and biological city established Chengdu Wesker biomedical Co., Ltd., which is planning and designing a production line with an annual output of hundreds of millions of needles, and will realize domestic independent research and development of the complete set of equipment. At present, in addition to using insect cells to produce new crown vaccines, the company is also using insect cell technology to produce rabies vaccine, influenza vaccine and herpes virus vaccine, etc. more than 20 innovative immunotherapy products such as various bacterial vaccines and various tumor vaccines are under research and development, and more than 40 patents have been obtained and applied for related products and technologies.

and

according to the introduction, Chengdu Tianfu international biological city is jointly constructed by Chengdu high tech Zone and Shuangliu District, with a planning area of about 44 square kilometers. It is committed to building a modern biological industry system with international competitiveness and regional driving force and building a world-class biological industry park. The vaccine industrialization project located in Chengdu Tianfu international bio city covers an area of 6000 square meters. Currently, the workshop design, equipment selection and environmental impact assessment are in progress. The plant is expected to be put into use by the end of the year.